X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11123) 11123
Magazine Article (73) 73
Book Chapter (12) 12
Publication (7) 7
Book / eBook (5) 5
Conference Proceeding (4) 4
Dissertation (3) 3
Book Review (2) 2
Streaming Video (2) 2
Web Resource (2) 2
Newsletter (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9174) 9174
levodopa - therapeutic use (7239) 7239
parkinson disease - drug therapy (6060) 6060
male (5659) 5659
female (5076) 5076
middle aged (4391) 4391
parkinson's disease (4207) 4207
aged (4035) 4035
clinical neurology (3922) 3922
antiparkinson agents - therapeutic use (3645) 3645
levodopa (3520) 3520
neurosciences (2545) 2545
levodopa - adverse effects (2089) 2089
adult (2084) 2084
parkinson disease - physiopathology (1984) 1984
animals (1936) 1936
dopamine (1411) 1411
antiparkinson agents - adverse effects (1323) 1323
pharmacology & pharmacy (1291) 1291
levodopa - administration & dosage (1286) 1286
neurology (1248) 1248
drug therapy, combination (1168) 1168
l-dopa (1159) 1159
parkinson disease - complications (1155) 1155
dopa (1119) 1119
treatment outcome (1072) 1072
parkinsons disease (1007) 1007
movement disorders (993) 993
carbidopa - therapeutic use (967) 967
levodopa - pharmacology (939) 939
parkinsons-disease (917) 917
parkinson’s disease (889) 889
rats (854) 854
dopamine agonists - therapeutic use (841) 841
double-blind (836) 836
psychiatry (809) 809
time factors (809) 809
basal ganglia (803) 803
parkinson disease - therapy (785) 785
dose-response relationship, drug (778) 778
dyskinesia (768) 768
aged, 80 and over (754) 754
motor fluctuations (750) 750
dopamine agents - therapeutic use (699) 699
neurodegenerative diseases (698) 698
antiparkinson agents - administration & dosage (688) 688
double-blind method (687) 687
severity of illness index (663) 663
dopamine - metabolism (656) 656
parkinson disease - diagnosis (652) 652
parkinson disease - metabolism (609) 609
drug combinations (589) 589
disease models, animal (564) 564
analysis (556) 556
therapy (533) 533
parkinson disease - psychology (524) 524
deep brain stimulation (514) 514
disease (509) 509
follow-up studies (489) 489
parkinson disease (487) 487
medicine & public health (484) 484
subthalamic nucleus (474) 474
antiparkinson agents - pharmacology (462) 462
drug therapy (447) 447
brain (446) 446
clinical trials as topic (437) 437
bromocriptine - therapeutic use (431) 431
care and treatment (416) 416
dyskinesia, drug-induced - etiology (412) 412
dyskinesia, drug-induced - drug therapy (409) 409
motor activity - drug effects (406) 406
parkinsonian disorders - drug therapy (394) 394
research (390) 390
surgery (388) 388
neurons (386) 386
quality of life (381) 381
nervous system diseases (377) 377
levodopa-induced dyskinesias (376) 376
levodopa-induced dyskinesia (362) 362
patients (359) 359
disease progression (355) 355
levodopa - pharmacokinetics (355) 355
magnetic resonance imaging (352) 352
phenols (348) 348
medicine, general & internal (345) 345
diagnosis (343) 343
selegiline - therapeutic use (342) 342
parkinson disease - pathology (341) 341
rats, sprague-dawley (340) 340
pharmacokinetics (334) 334
adolescent (332) 332
mice (332) 332
parkinsonism (330) 330
research article (328) 328
pramipexole (326) 326
progression (322) 322
risk factors (318) 318
drug administration schedule (317) 317
benserazide - therapeutic use (315) 315
dopamine agonists (312) 312
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10153) 10153
French (227) 227
German (212) 212
Spanish (201) 201
Russian (172) 172
Japanese (166) 166
Italian (82) 82
Polish (63) 63
Portuguese (39) 39
Chinese (35) 35
Dutch (22) 22
Hungarian (14) 14
Finnish (10) 10
Danish (9) 9
Norwegian (9) 9
Swedish (9) 9
Czech (8) 8
Serbian (7) 7
Hebrew (6) 6
Romanian (5) 5
Slovak (2) 2
Croatian (1) 1
Lithuanian (1) 1
Slovenian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 11/2016, Volume 2016, Issue 11, p. CD010690
Journal Article
2008, Volume 25, Issue 8, 18
Psychotic symptoms in Parkinson's disease (PD) are relatively common and, in addition to creating a disturbance in patients' daily lives, have consistently... 
Antipsychotics | Olanzapine | Parkinson's disease | Rivastigmine | Ziprasidone | Schizophrenia | Clozapine | Aripiprazole | Risperidone | Quetiapine | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Geriatrics/Gerontology | Clozapine, therapeutic use | Antipsychotics, therapeutic use | Olanzapine, therapeutic use | Quetiapine, therapeutic use | Parkinson's disease, treatment | Aripiprazole, therapeutic use | Risperidone, therapeutic use | Rivastigmine, therapeutic use | APOLIPOPROTEIN-E EPSILON-4 | NURSING-HOME PLACEMENT | VISUAL HALLUCINATIONS | DRUG-INDUCED PSYCHOSIS | DOPAMINERGIC-INDUCED HALLUCINATIONS | FOLLOW-UP | PHARMACOLOGY & PHARMACY | DEEP BRAIN-STIMULATION | INDUCED PSYCHIATRIC STATES | LEVODOPA-INDUCED PSYCHOSIS | LEWY BODY DEMENTIA | GERIATRICS & GERONTOLOGY | Parkinson Disease - therapy | Parkinson Disease - complications | Humans | Risk Factors | Clinical Trials as Topic | Parkinson Disease - physiopathology | Parkinson Disease - psychology | Psychotic Disorders - therapy | Antidepressive Agents - therapeutic use | Antipsychotic Agents - therapeutic use | Ondansetron - therapeutic use | Electroconvulsive Therapy | Cholinesterase Inhibitors - therapeutic use | Psychotic Disorders - etiology | Complications and side effects | Antipsychotic drugs | Psychoses | Dosage and administration | Drug therapy | Health aspects | Risk factors
Book Review
Expert Opinion on Drug Metabolism & Toxicology, ISSN 1744-7607, 2013, Volume 9, Issue 7, pp. 859 - 874
Introduction: The development of pharmacogenetic-based clinical practice guidelines for the use of anti-Parkinson's disease drugs requires, as a pre-requisite, the identification and validation of genetic biomarkers... 
adverse drug reactions | Parkinson's disease | pharmacogenomics | biomarkers | pharmacogenetics | Biomarkers | Pharmacogenetics | Adverse drug reactions | Pharmacogenomics | HUMAN PLASMA | INTRAETHNIC VARIABILITY | BIOCHEMISTRY & MOLECULAR BIOLOGY | AMANTADINE ACETYLATION | SINGLE-DOSE PHARMACOKINETICS | CLINICAL PHARMACOKINETICS | DECARBOXYLASE INHIBITOR | LEVODOPA THERAPY | CATECHOL-O-METHYLTRANSFERASE | METABOLISM | PHARMACOLOGY & PHARMACY | TOXICOLOGY | HEALTHY-VOLUNTEERS | Humans | Receptors, Dopamine D3 - metabolism | Aryl Hydrocarbon Hydroxylases - genetics | Parkinson Disease - drug therapy | Receptors, Dopamine D2 - metabolism | Indans - therapeutic use | Bromocriptine - therapeutic use | Pramipexole | Cytochrome P-450 CYP1A2 Inhibitors | Lisuride - therapeutic use | Receptors, Dopamine D3 - genetics | Cytochrome P-450 CYP3A - genetics | Catechols - therapeutic use | Selegiline - therapeutic use | Benztropine - therapeutic use | Reproducibility of Results | Levodopa - therapeutic use | Genetic Markers | Parkinson Disease - genetics | Cytochrome P-450 CYP1A2 - metabolism | Pergolide - therapeutic use | Receptors, Dopamine D2 - genetics | Aryl Hydrocarbon Hydroxylases - metabolism | Ergolines - therapeutic use | Cytochrome P-450 CYP2C19 | Cytochrome P-450 CYP3A - metabolism | Indoles - therapeutic use | Benzothiazoles - therapeutic use | Cabergoline | Cytochrome P-450 CYP2B6 | Nitriles - therapeutic use | Index Medicus
Journal Article
Movement disorders, ISSN 1531-8257, 2005, Volume 20, Issue 5, pp. 523 - 539
The objective of this study is to update a previous evidence‐based medicine (EBM) review on Parkinson's disease (PD) treatments, adding January 2001 to January... 
evidence‐based medicine | Parkinson's disease | levodopa | monoamine oxidase inhibitors | COMT inhibitors | amantadine | neurosurgery | dopamine agonists | anticholinergics | deep brain stimulation | neurotransplantation | Anticholinergics | Amantadine | Monoamine oxidase inhibitors | Deep brain stimulation | Dopamine agonist | Neurotransplantation | Levodopa | Neurosurgery | Evidence-based medicine | CONTROLLED-TRIAL | SUBTHALAMIC NUCLEUS STIMULATION | DAYTIME SLEEPINESS | dopan-tine agonists | RANDOMIZED-TRIAL | INITIAL TREATMENT | COGNITIVE FUNCTION | CLINICAL NEUROLOGY | EMBRYONIC DOPAMINE NEURONS | MOTOR FLUCTUATIONS | DOUBLE-BLIND | evidence-based medicine | Mesencephalon - cytology | Humans | Parkinson Disease - drug therapy | Piribedil - therapeutic use | Apomorphine - therapeutic use | Thiazoles - therapeutic use | Amantadine - therapeutic use | Indans - therapeutic use | Bromocriptine - therapeutic use | Antiparkinson Agents - therapeutic use | Lisuride - therapeutic use | Nitrophenols - therapeutic use | Fetal Tissue Transplantation - methods | Selegiline - therapeutic use | Monoamine Oxidase Inhibitors - therapeutic use | Benzophenones - therapeutic use | Levodopa - therapeutic use | Pergolide - therapeutic use | Deep Brain Stimulation - methods | Ergolines - therapeutic use | Parkinson Disease - surgery | Mesencephalon - embryology | Globus Pallidus - surgery | Indoles - therapeutic use | Catechol O-Methyltransferase Inhibitors | Neurosurgical Procedures - methods | Dihydroergocryptine - therapeutic use | Benzothiazoles
Journal Article
Journal Article
Drugs & Aging, ISSN 1170-229X, 09/2000, Volume 17, Issue 3, pp. 165 - 181
Early and correct diagnosis and treatment of Parkinson's disease (PD) are crucial for the patient's well being. At the first visit, it is important to deal... 
Benzatropine, therapeutic use | Carbidopa, therapeutic use | NMDA antagonists, therapeutic use | Anticholinergics, therapeutic use | Cabergoline, therapeutic use | Amantadine, therapeutic use | Tolcapone, therapeutic use | Ropinirole, therapeutic use | Neurosurgery | Parkinson's disease, diagnosis | Biperiden, therapeutic use | Neuroprotectants, therapeutic use | Orphenadrine, therapeutic use | Entacapone, therapeutic use | Trihexyphenidyl, therapeutic use | Parkinson's disease, treatment | Tocopherol, therapeutic use | Bromocriptine, therapeutic use | Procyclidine, therapeutic use | Pergolide, therapeutic use | Ascorbic acid, therapeutic use | Pramipexole, therapeutic use | Levodopa, therapeutic use | Antiparkinsonians, therapeutic use | Dopamine agonists, therapeutic use | Midodrine, therapeutic use | COMT inhibitors, therapeutic use | Monoamine oxidase inhibitors, therapeutic use | Modafinil, therapeutic use | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Geriatrics/Gerontology | CENTRAL PATHOPHYSIOLOGICAL MECHANISMS | MOVEMENT-DISORDERS | SUBTHALAMIC NUCLEUS | DOPAMINE AGONIST | XENOBIOTIC METABOLISM | BASAL GANGLIA | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | MITOCHONDRIAL-DNA | YOUNG-ONSET | I-123 BETA-CIT | GERIATRICS & GERONTOLOGY | Antiparkinson Agents - therapeutic use | Animals | Free Radicals | Levodopa - therapeutic use | Humans | Dopamine Agonists - therapeutic use | Parkinson Disease - diagnosis | Catechol O-Methyltransferase Inhibitors | Parkinson Disease - drug therapy | Cholinergic Antagonists - therapeutic use | Parkinson Disease - etiology
Journal Article
Journal of neurochemistry, ISSN 0022-3042, 2016, Volume 139, Issue S1, pp. 325 - 337
Journal Article